NCT05859919View on ClinicalTrials.gov

"Conducting Clinical Trials of the Medicine Rutan Tablets 0.1g No. 10 in the Complex Therapy of COVID-19"

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

October 12, 2020

Primary Completion Date

September 30, 2021

Study Completion Date

September 30, 2021

Conditions
Patients With COVID-19
Interventions
DRUG

"The drug Rutan 0.1."

"Active ingredient: (3,6-bis-O-galloyl-1,2,4-tri-O-galloyl-β-D-glucose). Active substance: Rutan 0.1 100mg. Excipients: potato starch, calcium stearate, lactulose."

OTHER

Basic treatment

"Basic treatment without the drug Rutan 0.1."

Trial Locations (1)

100194

Erkin Musabaev, Tashkent

All Listed Sponsors
lead

Research Institute of Virology, Ministry of Health of the Republic of Uzbekistan

OTHER_GOV

NCT05859919 - "Conducting Clinical Trials of the Medicine Rutan Tablets 0.1g No. 10 in the Complex Therapy of COVID-19" | Biotech Hunter | Biotech Hunter